Cotargeting NSD1/2 paralogs in AR-driven castration-resistant prostate cancer

The University of Michigan's Regents received a $1.84 million Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), effective September 1, 2025 through August 31, 2028. The award supports research focused on co-targeting NSD1/2 paralogs in androgen receptor (AR)-driven castration-resistant prostate cancer. This research initiative represents a translational oncology effort designed to advance therapeutic development and biomarker discovery for an aggressive form of prostate cancer resistant to standard hormonal treatments, aligned with the Defense Health Agency's mission to transform healthcare for service members and the American public through innovative biomedical research solutions.

The research will be conducted at the University of Michigan's Ann Arbor campus through the Office of Research and Sponsored Projects Division. As a major research institution with annual research expenditures exceeding $1.77 billion, the University of Michigan demonstrates substantial capability in hypothesis-driven cancer research and translational investigations. This award follows the Military Medical Research and Development program's standard two-tier competitive review process, emphasizing technical merit and military relevance, with a typical performance period of three years consistent with program guidelines for awards in this funding range.